scholarly journals Association between Previous Statin Use and Alzheimer’s Disease: A Nested Case-Control Study Using a National Health Screening Cohort

2021 ◽  
Vol 11 (3) ◽  
pp. 396
Author(s):  
Ji Hee Kim ◽  
Heui Seung Lee ◽  
Jee Hye Wee ◽  
Yoo Hwan Kim ◽  
Chan Yang Min ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Blood Pressure ◽  
Alzheimer's Disease ◽  
National Health ◽  
Total Cholesterol Level ◽  
Conditional Logistic Regression ◽  
Fasting Blood Glucose ◽  
Control Group ◽  
Conditional Logistic Regression Model ◽  
Statin Use

A number of studies report the incidence of Alzheimer’s disease (AD) in patients taking statins, but the results are inconsistent. (1) Background: The present study investigated the cross-sectional association between previous statin use and the risk of AD development in Korean residents. (2) Methods: We used the Korean National Health Insurance Service-National Sample Cohort; 17,172 AD patients were matched by age, gender, income, and region of residence with 68,688 control participants at a ratio of 1:4. We used a multiple conditional logistic regression model to analyse the association between the number of days of statin use and AD occurrence. Further analyses were performed to identify whether this association is maintained for different ages, genders, socioeconomic status groups, and covariates. (3) Results: The odds ratio, which was adjusted for potential confounders, for the days of statin use per year in the AD group compared to the control group was 0.95 (95% confidence interval = 0.92–0.98; p = 0.003). The number of days of statin use in the AD group was significantly smaller in the subgroups of non-smokers and individuals with normal weight, alcohol consumption less than once a week, total cholesterol level below 200 mg/dL, systolic blood pressure below 140, diastolic blood pressure below 90, and fasting blood glucose below 100 mg/dL. (4) Conclusions: Our results suggest that statin use prevents the occurrence of AD. The effects of statin use in preventing AD may be greater in individuals at relatively low risk.

scholarly journals Association Between Previous Statin Use and Alzheimer’s Disease: A Nested Case-control Study Using a National Health Screening Cohort

2020 ◽  
Author(s):  
Ji Hee Kim ◽  
Heui Seung Lee ◽  
Jee Hye Wee ◽  
Chan Yang Min ◽  
Dae Myoung Yoo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Blood Pressure ◽  
Alzheimer's Disease ◽  
National Health ◽  
Total Cholesterol Level ◽  
Conditional Logistic Regression ◽  
Fasting Blood Glucose ◽  
Control Group ◽  
Conditional Logistic Regression Model ◽  
Statin Use

Abstract BackgroundA number of studies on the incidence of Alzheimer’s disease (AD) in patients taking statins have been reported; however, the results are inconsistent. This study aimed to investigate the association between previous statin use and the risk of AD development in Korean residents.MethodsWe assessed the Korean National Health Insurance Service-National Sample Cohort, which includes individuals aged older than 40 years from 2002 to 2015. A total of 17,172 AD patients were matched by age, sex, income, and region of residence with 68,688 control participants at a ratio of 1:4. We used a multiple conditional logistic regression model to analyze the association between the number of days of statin use and AD occurrence. Further analyses were performed to identify whether this association was maintained for different ages, sexes, socioeconomic statuses, and covariates.ResultsThe adjusted odds ratio (OR), which was adjusted for potential confounders, for the days of statin use per year in the AD group compared to the control group was 0.95 (95% confidence interval [CI] = 0.92-0.98, P = 0.003). The number of days of statin use in the AD group was significantly smaller than that in control group among women older than 75 years and in the subgroups of nonsmokers and individuals with normal weight, alcohol consumption less than once a week, total cholesterol level below 200, systolic blood pressure below 140 and diastolic blood pressure below 90, and fasting blood glucose below 100.ConclusionsOur results suggested that statin use may prevent the occurrence of AD. The effect of preventing AD in statin use may be greater in individuals with relatively low risk.

scholarly journals Association between Osteoporosis and Low Hemoglobin Levels: A Nested Case–Control Study Using a National Health Screening Cohort

2021 ◽  
Vol 18 (16) ◽  
pp. 8598
Author(s):  
So-Young Kim ◽  
Dae-Myoung Yoo ◽  
Chanyang Min ◽  
Hyo-Geun Choi
Keyword(s):  
Blood Pressure ◽  
National Health ◽  
Smoking Status ◽  
Conditional Logistic Regression ◽  
Adult Population ◽  
Fasting Blood Glucose ◽  
Health Screening ◽  
Charlson Comorbidity Index Score ◽  
Conditional Logistic Regression Model ◽  
Increased Risk

An association between anemia and an increased risk of osteoporosis has been suggested. The goal of this study was to estimate the association of hemoglobin (Hb) level with osteoporosis. A total of 69,760 osteoporosis patients aged ≥ 40 years old from the Korean National Health Insurance Service Health Screening Cohort were enrolled. From an identical cohort database, 69,760 comparison participants were randomly selected. Hb levels before the onset of osteoporosis were evaluated. The association of Hb level with osteoporosis was analyzed using a conditional logistic regression model adjusted for obesity, smoking status, alcohol consumption, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, and the Charlson comorbidity index score. Fifteen percent of the osteoporosis group and 14.17% of the comparison group had anemia. The Hb level was associated with 0.98-fold lower odds for osteoporosis (95% confidence intervals = 0.97–0.99, p < 0.001). A low Hb level was associated with a high risk of osteoporosis in the adult population. There was a consistent association between a low Hb level and osteoporosis in patients with comorbidities.

Association between statin use and the risks of glaucoma in Australia: a 10-year cohort study

2021 ◽  
pp. bjophthalmol-2021-318789
Author(s):  
Yixiong Yuan ◽  
Wei Wang ◽  
Xianwen Shang ◽  
Ruilin Xiong ◽  
Jason Ha ◽  
...  
Keyword(s):  
Large Scale ◽  
Conditional Logistic Regression ◽  
Control Group ◽  
Case Group ◽  
Conditional Logistic Regression Model ◽  
The People ◽  
Increased Risk ◽  
Nested Case Control ◽  
Statin Use

SynopsisIn a cohort of middle-aged and elderly Australians, we found that long-term statin use was associated with a higher risk of glaucoma onset. As to subtypes of statins, the increased risk was only found in rosuvastatin users.PurposeTo investigate the relationship between statin use and glaucoma onset in a 10-year longitudinal study.MethodsThis nested case–control study was based on data from a large-scale cohort of Australians aged over 45 years old. Medication exposure was identified by claims records from the Pharmaceutical Benefits Scheme during the follow-up period (2009–2016). The onset of glaucoma was defined as the people with at least three claims of antiglaucoma medications. Controls matched by age, gender and cardiovascular diseases were selected from participants without prescription of antiglaucoma medications. A conditional logistic regression model was used to assess the association between statin use and glaucoma onset.ResultsThe proportion of statin users was higher in the case group (40.5%) than that in the control group (38.4%). After adjusting for baseline characteristics and longitudinal claims records, statin use was not associated with glaucoma onset (OR 1.04, 95% CI 0.97 to 1.11). However, an increased risk of glaucoma onset was observed in participants with a longer duration of statin use (>3 years vs <1 year: OR 1.12, 95% CI 1.04 to 1.21). With respect to specific types of statins, participants taking rosuvastatin were more likely to suffer from glaucoma (OR 1.11, 95%CI 1.01 to 1.22). The use of other statins was not significantly associated with glaucoma onset.ConclusionsLong-term statin use was found to be associated with a higher risk of glaucoma onset in this study. Regarding specific types of statins, the increased risk of glaucoma onset was only observed in users of rosuvastatin.

scholarly journals Increased Risk of Migraine in Patients with Temporomandibular Disorder: A Longitudinal Follow-Up Study Using a National Health Screening Cohort

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 724
Author(s):  
Soo-Hwan Byun ◽  
Chanyang Min ◽  
Dae-Myoung Yoo ◽  
Byoung-Eun Yang ◽  
Hyo-Geun Choi
Keyword(s):  
Blood Pressure ◽  
National Health ◽  
Temporomandibular Disorder ◽  
Fasting Blood Glucose ◽  
Health Screening ◽  
Control Group ◽  
Follow Up Study ◽  
Kaplan Meier ◽  
Increased Risk

Background: The aim of this study was to investigate the association between temporomandibular disorder (TMD) and migraine through a longitudinal follow-up study using population data from a national health screening cohort. Methods: This cohort study used data from the Korean National Health Insurance Service-Health Screening Cohort from 2002 to 2015. Of the 514,866 participants, 3884 TMD patients were matched at a 1:4 ratio with 15,536 control participants. Crude models and models adjusted for obesity, smoking, alcohol consumption, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, and Charlson Comorbidity Index (CCI) scores were calculated. Chi-squared test, Kaplan–Meier analysis, and two-tailed log-rank test were used for statistical analysis. Stratified Cox proportional hazard models were used to assess hazard ratios (HR) and 95% confidence intervals (CIs) for migraine in both control groups. Results: The adjusted HR for migraine was 2.10 (95% CI: 1.81–2.44) in the TMD group compared to the control group, which was consistent in subgroup analyses according to age, sex, and Kaplan–Meier analysis. Conclusions: This study demonstrated that TMD patients have a higher risk of migraine. These results suggest that dentists can decrease the risk of migraine in TMD patients by managing TMD properly.

scholarly journals Association between statin medication and hearing impairment in a national health screening cohort

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
So Young Kim ◽  
Chang Ho Lee ◽  
Chanyang Min ◽  
Dae Myoung Yoo ◽  
Hyo Geun Choi
Keyword(s):  
Hearing Impairment ◽  
National Health ◽  
Conditional Logistic Regression ◽  
Adult Population ◽  
Population Data ◽  
Health Screening ◽  
National Registry ◽  
Control Group ◽  
Statin Prescription ◽  
Statin Use

AbstractThis study aimed to investigate the association of previous stain use with hearing impairment in an adult population. Data from the ≥ 40-year-old population in the Korean National Health Insurance Service Health Screening Cohort were used. The hearing impairment group was classified based on the national registry of hearing-impaired persons. Control participants were randomly selected and matched for age, sex, income, and region of residence. The number of days of statin prescription during the 2 years before the diagnosis of hearing impairment was compared between the hearing impairment group and the control group using conditional logistic regression analysis. Additional analyses were conducted according to age and sex. The number of days of previous statin use was not different between the hearing impairment group and the control group (adjusted odds ratio [aOR] = 0.94, 95% confidence interval (CI) = 0.86–1.02, P = 0.118). According to age, in the ≥ 70-year-old group, those with hearing impairment had 11% lower rates of previous statin use than those in the control group (aOR = 0.89, 95% CI = 0.80–0.99, P = 0.039). According to sex, in the male group, 12% lower rates of previous statin use were observed among those with hearing impairment than among those in the control group (aOR = 0.88, 95% CI = 0.79–0.99, P = 0.037). Previous statin use might have an effect on reducing the prevalence of hearing impairment in elderly individuals and men.

Increased Prevalence of Vestibular Loss in Mild Cognitive Impairment and Alzheimer’s Disease

2020 ◽  
Vol 16 (12) ◽  
pp. 1143-1150 ◽  
Author(s):  
Eric X. Wei ◽  
Esther S. Oh ◽  
Aisha Harun ◽  
Matthew Ehrenburg ◽  
Qian-Li Xue ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Conditional Logistic Regression ◽  
Vestibular Function ◽  
Cognitive Status ◽  
Control Group ◽  
Vestibular Loss ◽  
Logistic Regression Models

Background/Aims:: Recent evidence has shown that Alzheimer’s Disease (AD) patients have reduced vestibular function relative to healthy controls. In this study, we evaluated whether patients with Mild Cognitive Impairment (MCI) also have reduced vestibular function relative to controls, and compared the level of vestibular impairment between MCI and AD patients. Methods:: Vestibular physiologic function was assessed in 77 patients (26 MCI, 51 AD) and 295 matched controls using 3 clinical vestibular tests. The association between vestibular loss and cognitive impairment was evaluated using conditional logistic regression models. Results:: Individuals with vestibular impairment had a 3 to 4-fold increased odds of being in the MCI vs. control group (p-values < 0.05). MCI patients had a level of vestibular impairment that was intermediate between controls and AD. Conclusion:: These findings suggest a dose-response relationship between vestibular loss and cognitive status, and support the hypothesis that vestibular loss contributes to cognitive decline.

Alzheimer’s Disease: Erythrocyte 2,3-diphosphoglycerate Content and Circulating Erythropoietin

2019 ◽  
Vol 16 (9) ◽  
pp. 834-835
Author(s):  
Petter Järemo ◽  
Alenka Jejcic ◽  
Vesna Jelic ◽  
Tasmin Shahnaz ◽  
Homira Behbahani ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Cell Damage ◽  
Control Group ◽  
Red Cell ◽  
Oxygen Release ◽  
Regulatory Pathways ◽  
Β Amyloid ◽  
2,3 Dpg

Background: Alzheimer’s Disease (AD) features the accumulation of β-amyloid in erythrocytes. The subsequent red cell damage may well affect their oxygen-carrying capabilities. 2,3- diphosphoglycerate (2,3-DPG) binds to the hemoglobin thereby promoting oxygen release. It is theorized that 2,3-DPG is reduced in AD and that the resulting hypoxia triggers erythropoietin (EPO) release. Methods & Objective: To explore this theory, we analyzed red cell 2,3-DPG content and EPO in AD, mild cognitive impairment, and the control group, subjective cognitive impairment. Results: We studied (i) 2,3-DPG in red cells, and (ii) circulating EPO in AD, and both markers were unaffected by dementia. Disturbances of these oxygen-regulatory pathways do not appear to participate in brain hypoxia in AD.

scholarly journals Women have Farther to Fall: Gender Differences Between Normal Elderly and Alzheimer's Disease in Verbal Memory Engender Better Detection of Alzheimer's Disease in Women

2011 ◽  
Vol 17 (4) ◽  
pp. 654-662 ◽  
Author(s):  
Robert M. Chapman ◽  
Mark Mapstone ◽  
Margaret N. Gardner ◽  
Tiffany C. Sandoval ◽  
John W. McCrary ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gender Differences ◽  
Verbal Memory ◽  
Control Group ◽  
Large Drop ◽  
Delayed Recall ◽  
Logical Memory ◽  
Wechsler Memory Scale ◽  
Immediate Recall

AbstractWe analyzed verbal episodic memory learning and recall using the Logical Memory (LM) subtest of the Wechsler Memory Scale-III to determine how gender differences in AD compare to those seen in normal elderly and whether or not these differences impact assessment of AD. We administered the LM to both an AD and a Control group, each comprised of 21 men and 21 women, and found a large drop in performance from normal elders to AD. Of interest was a gender interaction whereby the women's scores dropped 1.6 times more than the men's did. Control women on average outperformed Control men on every aspect of the test, including immediate recall, delayed recall, and learning. Conversely, AD women tended to perform worse than AD men. Additionally, the LM achieved perfect diagnostic accuracy in discriminant analysis of AD versus Control women, a statistically significantly higher result than for men. The results indicate the LM is a more powerful and reliable tool in detecting AD in women than in men. (JINS, 2011, 17, 654–662)

Sign in / Sign up

Export Citation Format

Share Document